Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
FibroGen’s $150 Million Financing with Morgan Stanley Tactical Value
FibroGen’s Royalty Monetization Financing with NovaQuest Capital Management
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
MorphoSys’ $1.7 Billion Acquisition of Constellation Pharmaceuticals
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...